>>ANN ARBOR, Mich., June 14 /PRNewswire-FirstCall/ -- Genomic Solutions Inc. (Nasdaq: GNSL - News), announced that it has received a deficiency notice from the Nasdaq Staff dated June 12, 2002 indicating that its common stock has failed to maintain a minimum bid price of $1.00 over the previous thirty (30) consecutive days as required by the Nasdaq National Market under Marketplace Rule 4450(a)(5).
The notice does not affect the availability of trading the company's stock and it remains listed on the Nasdaq National Market. The company has, in accordance with Market Place Rule 4450(e)(2), ninety (90) calendar days to regain compliance. The company is evaluating alternatives in response to this notice.
Genomic Solutions develops, manufactures, and sells instruments, software, and consumables used to determine the activity level of genes, to isolate, identify and characterize proteins, and to dispense small volumes of biologically important materials.<<
snip |
